Novo Nordisk Sets Ambitious 2030 Goals: 5+ Blockbusters, 10x Obesity Capacity — Novo Nordisk

Event summary

Novo Nordisk hosted its Capital Markets Day 2026 in London on September 21, 2026.
The company outlined strategic ambitions for 2030, including launching >5 multi-blockbusters and achieving >150 bDKK pipeline sales by 2035.
Key goals include serving >60m patients globally by 2030 and scaling capacity to serve 10x more people with obesity on oral GLP-1.
Novo Nordisk aims to deliver 2026-30 revenue CAGR in line with industry peers and maintain a broadly stable operating margin.

The big picture

Novo Nordisk's 2030 strategic ambitions reflect the intense competition in the pharmaceutical sector, particularly in obesity and diabetes treatments. The company's focus on pipeline diversification and capacity expansion underscores the need to maintain leadership in high-growth therapy areas while delivering sustainable financial returns. The comparison to industry peers highlights the pressure to keep pace with innovation and market share gains.

What we're watching

Pipeline Execution: Whether Novo Nordisk can deliver on its ambitious pipeline goals, including >5 Phase 3 programs in obesity, diabetes, and other therapy areas.
Market Competition: How Novo Nordisk will differentiate itself against industry peers like Eli Lilly and AstraZeneca in achieving revenue CAGR alignment.
Operational Scaling: The pace at which Novo Nordisk can scale its manufacturing and supply chain to meet the goal of serving 10x more obesity patients on oral GLP-1.